Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

145 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Corrigendum to "Toll-like receptor 3 downregulation is an escape mechanism from apoptosis during hepatocarcinogenesis" [J Hepatol 71 (2019) 763-772].
Bonnin M, Fares N, Testoni B, Estornes Y, Weber K, Vanbervliet B, Lefrançois L, Garcia A, Kfoury A, Pez F, Coste I, Saintigny P, Viari A, Lang K, Guey B, Petrilli V, Hervieu V, Bancel B, Bartosch B, Durantel D, Renno T, Merle P, Lebecque S. Bonnin M, et al. Among authors: fares n. J Hepatol. 2020 Mar;72(3):594. doi: 10.1016/j.jhep.2019.11.001. Epub 2019 Nov 25. J Hepatol. 2020. PMID: 31780083 No abstract available.
Real-life data on biliary tract cancers in France: The nested Amber study from the French ACABi GERCOR PRONOBIL retro-prospective, observational cohort.
Delaye M, Boilève A, Henriques J, Rouault A, Paccard JR, Fares N, Assenat E, Lecomte T, Hautefeuille V, Tougeron D, Edeline J, Boileau C, Ducroux A, Hollebecque A, Vernerey D, Turpin A, Neuzillet C. Delaye M, et al. Among authors: fares n. Dig Liver Dis. 2025 Jan;57(1):111-117. doi: 10.1016/j.dld.2024.06.032. Epub 2024 Jul 14. Dig Liver Dis. 2025. PMID: 39004550 Free article.
Management of biliary tract cancers in early-onset patients: A nested multicenter retrospective study of the ACABI GERCOR PRONOBIL cohort.
Lebeaud A, Antoun L, Paccard JR, Edeline J, Bourien H, Fares N, Tournigand C, Lecomte T, Tougeron D, Hautefeuille V, Viénot A, Henriques J, Williet N, Bachet JB, Smolenschi C, Hollebecque A, Macarulla T, Castet F, Malka D, Neuzillet C, Vernerey D, Boilève A, Turpin A. Lebeaud A, et al. Among authors: fares n. Liver Int. 2024 Aug;44(8):1886-1899. doi: 10.1111/liv.15922. Epub 2024 Apr 8. Liver Int. 2024. PMID: 38588031
Alteration of splicing factors' expression during liver disease progression: impact on hepatocellular carcinoma outcome.
Wang H, Lekbaby B, Fares N, Augustin J, Attout T, Schnuriger A, Cassard AM, Panasyuk G, Perlemuter G, Bieche I, Vacher S, Selves J, Péron JM, Bancel B, Merle P, Kremsdorf D, Hall J, Chemin I, Soussan P. Wang H, et al. Among authors: fares n. Hepatol Int. 2019 Jul;13(4):454-467. doi: 10.1007/s12072-019-09950-7. Epub 2019 May 28. Hepatol Int. 2019. PMID: 31140152
Toll-like receptor 3 downregulation is an escape mechanism from apoptosis during hepatocarcinogenesis.
Bonnin M, Fares N, Testoni B, Estornes Y, Weber K, Vanbervliet B, Lefrançois L, Garcia A, Kfoury A, Pez F, Coste I, Saintigny P, Viari A, Lang K, Guey B, Hervieu V, Bancel B, Bartoch B, Durantel D, Renno T, Merle P, Lebecque S. Bonnin M, et al. Among authors: fares n. J Hepatol. 2019 Oct;71(4):763-772. doi: 10.1016/j.jhep.2019.05.031. Epub 2019 Jun 18. J Hepatol. 2019. PMID: 31220470
145 results